Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Lepu Biopharma Co. Ltd. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 5 distinct art units, indicating that the portfolio’s pending work is distributed across separate examination assignments.
HADDAD, MAHER M is the busiest examiner, with 1 pending action. Because the recorded pending-action count is evenly distributed among the examiners, counsel should use matter-specific prosecution strategies rather than rely on a single examiner profile.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700213 | CD3-TARGETING T-CELL ENGAGERS WITH IMPROVED THERAPEUTIC INDEX | HADDAD, MAHER M | — |
| 18692051 | USE OF ANTIBODY-DRUG CONJUGATE, AND COMBINED DRUG AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700235 | ANTI-CD3 ANTIBODIES WITH CROSS-REACTIVITY TO HUMAN AND CYNOMOLGUS PROTEINS | DEBERRY, REGINA M | — |
| 18700213 | CD3-TARGETING T-CELL ENGAGERS WITH IMPROVED THERAPEUTIC INDEX | HADDAD, MAHER M | — |
| 18692051 | USE OF ANTIBODY-DRUG CONJUGATE, AND COMBINED DRUG AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| 18582571 | TUMOR ANTIGEN-DEPENDENT CD40 AGONISTS ANTIBODIES | REDDIG, PETER J | — |
| 17997775 | ANTIBODY-DRUG CONJUGATE AND PREPARATION THEREOF | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1641 | 1 |
| 1643 | 1 |
| 1646 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700235 | ANTI-CD3 ANTIBODIES WITH CROSS-REACTIVITY TO HUMAN AND CYNOMOLGUS PROTEINS | DEBERRY, REGINA M | 1647 | §112 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18700213 | CD3-TARGETING T-CELL ENGAGERS WITH IMPROVED THERAPEUTIC INDEX | HADDAD, MAHER M | 1641 | §102§112 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18692051 | USE OF ANTIBODY-DRUG CONJUGATE, AND COMBINED DRUG AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18582571 | TUMOR ANTIGEN-DEPENDENT CD40 AGONISTS ANTIBODIES | REDDIG, PETER J | 1646 | DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 17997775 | ANTIBODY-DRUG CONJUGATE AND PREPARATION THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLepu Biopharma Co. Ltd. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Regina M Deberry has the most, with 1 of Lepu Biopharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
